View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
July 1, 2020

Will Zeposia change the treatment paradigm in IBD?

By Victoria Smith

At present, there is an unmet need for novel oral drug formulations in inflammatory bowel disease (IBD) patients suffering from moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD). Key opinion leaders (KOLs) interviewed by GlobalData in Q2 2020 determine that sufferers would prefer an oral formulation over the current subcutaneously or intravenously delivered agents, due to less concern surrounding immunogenicity. Furthermore, the route of administration is simpler.

Last month, Bristol-Myers Squibb announced positive topline results from its pivotal Phase III TRUE NORTH trial in 1,012 patients evaluating Zeposia (ozanimod), an oral sphingosine1‐phosphate (S1P), in patients with moderate-to-severe UC. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU